Pharmaceutical firm Affymax continued its decline after it fired nearly three fourths of its labor complement and is now in the process of opting for a sale or declaration of bankruptcy. This low point was reached after its only drug was recalled for medical issues.
Share prices fell 64% to US$1.05 at its close in the NYSE index, its lowest since the company was listed on the bourse. In the past year, the company's share prices have fallen 73% overall. This was due to the recall of its anemia treatment drug Ormontys on reason of hypersensitivity reactions.
According to John Orwin, CEO of Affymax, "While the decision was extremely difficult, aligning and managing our limited resources around our product investigation is our most important priority." The company has laid off nearly 230 positions and is now considering options either a sale of company or assets, to restructure, wind down operations and possibly bankruptcy.
Join the Conversation